Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
vTv Therapeutics
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of disease
Mini Mental State Examination (MMSE) score of 21-26, inclusive
Clinical Dementia Rating global score of 0.5 or 1
Rosen-Modified Hachinski Ischemia Score less than or equal to 4
Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD
Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least 3 months prior to randomization
Caregiver willing to participate and be able to attend clinic visits with patient
Ability to ingest oral medications
You may not be if
Significant neurological or psychiatric disease other than Alzheimer's disease
Participants with evidence or history of severe drug allergies (resulting in dyspnea or severe rash).
Any contraindications to MRI (e.g., clinically significant claustrophobia, non-removable ferromagnetic implants). Patients with contraindications to MRI may undergo computed tomography (CT) on approval by sponsor.
Any contraindications to the FDG-PET study (e.g. allergy to any component of the FDG dose) in the cohort undergoing a PET scan.
Previous exposure to investigational or non-investigational therapies for Alzheimer's disease within 6 months of screening
History of cancer within the last 5 years except adequately treated cervical carcinoma in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate cancer not requiring treatment
